Literature DB >> 12475533

Should breast screening programmes limit their detection of ductal carcinoma in situ?

A J Evans1, R G Blanks.   

Abstract

OBJECTIVE: Previous research has shown that the detection of ductal carcinoma in situ (DCIS) aids the detection of small invasive cancers at mammographic screening. A correlation may therefore exist between a screening unit's DCIS detection rate and their small invasive cancer detection rate. We have therefore investigated the effect of DCIS detection rate on the detection of small (<15 mm) invasive cancers in the 95 units of the U.K. NHS Breast Screening Programme (NHSBSP).
MATERIALS AND METHODS: DCIS detection rates were examined against large (> or =15 mm) and small (<15 mm) invasive cancer detection rates in women aged 50-64 years at prevalent and incident screens over a 3-year period.
RESULTS: After adjusting for background incidence, screening units with the highest DCIS detection of > or =1.3/1000 detected over 20% more small invasive cancers than units with DCIS detection rates within the NHSBSP guidelines of 0.5-1/1000 (P<0.001). Sixty percent of units had DCIS detection rates above the guidelines. There was no correlation between DCIS detection and > or =15 mm invasive cancer detection. The results suggest that over the range of DCIS rates studied, that for every two extra DCIS cancers detected, an additional small invasive cancer (<15 mm) is detected that may otherwise not have been. The results therefore provide supporting evidence that the detection of DCIS aids the detection of small invasive cancers.
CONCLUSION: Units with DCIS detection above the NHSBSP guidelines have significantly better small invasive cancer detection rates. The existence of an upper limit for DCIS detection within the NHSBSP may be preventing the detection of small invasive cancers, because units are not recalling some small clusters of calcification in order to keep DCIS detection rates down. The upper limit may therefore be inappropriate.

Entities:  

Mesh:

Year:  2002        PMID: 12475533     DOI: 10.1053/crad.2002.1097

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  7 in total

Review 1.  Mode of detection and secular time for ductal carcinoma in situ.

Authors:  Etta D Pisano
Journal:  J Natl Cancer Inst Monogr       Date:  2010

2.  An analysis of 11.3 million screening tests examining the association between recall and cancer detection rates in the English NHS breast cancer screening programme.

Authors:  R G Blanks; R M Given-Wilson; S L Cohen; J Patnick; R J Alison; M G Wallis
Journal:  Eur Radiol       Date:  2019-02-04       Impact factor: 5.315

3.  In patients with DCIS: is it sufficient to histologically examine only those tissue specimens that contain microcalcifications?

Authors:  Alexander Poellinger; Susanne Diekmann; Ekkehart Dietz; Ulrich Bick; Felix Diekmann
Journal:  Eur Radiol       Date:  2008-01-08       Impact factor: 5.315

4.  Independent predictors of breast malignancy in screen-detected microcalcifications: biopsy results in 2545 cases.

Authors:  G Farshid; T Sullivan; P Downey; P G Gill; S Pieterse
Journal:  Br J Cancer       Date:  2011-11-03       Impact factor: 7.640

Review 5.  Overdiagnosis and overtreatment of breast cancer: is overdiagnosis an issue for radiologists?

Authors:  Ruth Warren; Asha Eleti
Journal:  Breast Cancer Res       Date:  2006-04-21       Impact factor: 6.466

6.  Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.

Authors:  Chris I Flowers; Cristina O'Donoghue; Dan Moore; Adeline Goss; Danny Kim; June-Ho Kim; Sjoerd G Elias; Julia Fridland; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2013-06-14       Impact factor: 4.872

Review 7.  The diagnosis and management of pre-invasive breast disease: radiological diagnosis.

Authors:  Andy Evans
Journal:  Breast Cancer Res       Date:  2003-07-29       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.